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Evaluation of the appropriateness of tirofiban use in accordance to current ACC/AHA guidelines
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Introduction
Figure 1. Comparison of Tirofiban infusion duration on different anti-platelet agents
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*Antiplatelet agents are given with Aspirin 325 mg

*All tirofiban doses are renally adjusted and given along with tirofiban bolus dose
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• A total of 6 patients (17.1%) were UA, 16 (45.7%) were NSTEMI,
and 13 (37.2%) were STEMI.
.
• All patients (N=35) were loaded with dual anti-platelet agents
when given tirofiban infusion.
• Each tirofiban infusion was given with HDB regimen and was
renally adjusted when appropriate.
• All patients had appropriate indications for tirofiban use, but the
duration of use varied.
• A total of 3 patients (8.6%) received infusion longer than 18 hours
and 14 (40%) patients received ≥ 11 hours of tirofiban infusion.
• All patients who received > 18 hours infusion were not candidates
of coronary artery bypass grafting.
• There was no evidence of thrombocytopenia (i.e. 50% drop in
platelets than baseline or platelets < 100,000/mm3) or bleeding
(i.e. signs of bleeding or administration of reversal agent)
complications post tirofiban infusion.
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Figure 3. Comparison of Measured Troponin-T and Duration of Tirofiban Infusion
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• Data was collected through retrospective chart review utilizing
computerized physician order entry (CPOE) and medical records.
• Patients were randomly selected from period of January 2015 to
July 2015 who received tirofiban infusion.
• Data collection included significant medical history, indication for
tirofiban use, laboratory values (troponin, platelets, renal
function), tirofiban infusion duration, anti-platelets used
concurrently and complications (i.e. bleeding and
thrombocytopenia) post tirofiban infusion.
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Figure 2. Comparison of Tirofiban use Indications

• Primary objective: To assess the appropriateness of tirofiban
utilizing the 2014 AHA/ACC guideline recommendations.
• Secondary objectives:
 To identify the indication for tirofiban use
 Duration of infusion post-PCI
 Other antiplatelet used in conjunction
 Assess complications such as bleeding or thrombocytopenia.
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• Tirofiban is a tyrosine-derived non-peptide Glycoprotein IIb/IIIa
(GP2b3a) inhibitor .
• GP2b3a inhibitor therapy during primary percutaneous coronary
intervention (PCI) decreases the incidence of major adverse
events as it directly affects the level of platelet inhibition.
• Currently tirofiban is approved for high-dose IV bolus (HDB)
regimen of 25mcg/kg within 5 minutes and then 0.15mcg/kg/min
infusion for up to 18 hours in patients with Non-ST-Elevation
Myocardial Infarction(NSTEMI) and Unstable Angina(UA)
undergoing Percutaneous Intervention(PCI).
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• Based on these results, standardization of tirofiban infusion
protocol will help with consistency in current practice.
• FABOLUS PRO trial has shown that tirofiban given as bolus only or
bolus followed by 2-hour infusion along with clopidogrel or
prasugrel leads to higher degree of platelet inhibition and obviates
the need of longer infusion in patients with STEMI.
• Studies further investigating similar strategies can help
standardize use and infusion duration to improve costeffectiveness without compromising quality of care.
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